One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry-Reference-Cited by-同舟云学术

One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry

Published:2023-09 Issue:9 Volume:130 Page:937-946
ISSN:0161-6420
Container-title:Ophthalmology
language:en
Short-container-title:Ophthalmology

Author:

MacCumber Mathew W.,Wykoff Charles C.^ORCID,Karcher Helene^ORCID,Adiguzel Eser^ORCID,Sinha Samriddhi Buxy^ORCID,Vishwakarma Saloni,LaPrise Andrew^ORCID,Igwe Franklin,Freitas Rita^ORCID,Ip Michael S.,Zarbin Marco A.^ORCID

Publisher

Elsevier BV

Subject

Ophthalmology

Reference38 articles.

1. Review of neovascular age-related macular degeneration treatment options;Holekamp;Am J Manag Care,2019

2. MacCumber M, Yu JS, Sagkriotis A, et al. Injection intervals in treatment-naive neovascular AMD patients who received anti-VEGF agents: an analysis of the IRIS® Registry. American Academy of Ophthalmology Annual Meeting Archive, 2019:PO471. Available at: https://secure.aao.org/aao/meeting-archive?_gl=1∗k75br9∗_ga∗MjIzNDUxNzY1LjE2ODE4MzkwMTI.∗_ga_3PN52QWGQQ∗MTY4NDM0NjEzNS4zLjAuMTY4NDM0NjEzNS42MC4wLjA. Accessed May 17, 2023.

3. Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis;MacCumber;Can J Ophthalmol,2023

4. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. 5-Year outcomes with anti-VEGF treatment of neovascular age-related macular degeneration (AMD): the Comparison of AMD Treatments Trials;Ophthalmology,2016

5. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration;Dugel;Ophthalmology,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evidence for brolucizumab efficacy in age-related macular degeneration and central serous chorioretinopathy patients;Heliyon;2024-05

2. Multi-registry analysis of patients with multiple sclerosis and neuromyelitis optica to improve capture of demographic data and compare visual outcomes;Multiple Sclerosis and Related Disorders;2024-04

3. Deep Learning-Based Ocular Disease Classification in Fundus Images;2023 IEEE Colombian Caribbean Conference (C3);2023-11-22

4. Efficacy and safety of treat-and-extend intravitreal Brolucizumab in naive and switched patients with macular neovascularization: one-year follow-up study.;2023-10-05

5. Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study;Pharmaceuticals;2023-06-26